In addition to changes among groups reflecting CRC progression (e.g., CA1, CLCA1, MATN2), we identified significant expression differences between individual patient tissues (e.g., SRSF3, OLFM4, CEACAM5), contributing to existing knowledge on patient-specific progression and highlighting the importance of paired samples for precision medicine. Here, SRSF3 is linked to colorectal carcinoma.